Stocks and Investing Stocks and Investing
Thu, March 2, 2017

Joseph Schwartz Upgraded (SRPT) to Buy and Increased Target to $47 on, Mar 2nd, 2017


Published on 2024-10-25 20:23:41 - WOPRAI, Joseph Schwartz
  Print publication without navigation


Joseph Schwartz of Leerink Swann, Upgraded "Sarepta Therapeutics, Inc." (SRPT) to Buy and Increased Target from $27 to $47 on, Mar 2nd, 2017.

Joseph has made no other calls on SRPT in the last 4 months.



There is 1 other peer that has a rating on SRPT. Out of the 1 peers that are also analyzing SRPT, 0 agree with Joseph's Rating of Hold.



This is the rating of the analyst that currently disagrees with Joseph


  • Anupam Rama of "JP Morgan" Initiated at Buy and Held Target at $40 on, Thursday, December 22nd, 2016

Contributing Sources